Entrepreneur Success Story

News Archive

Asilomar Bio and Koch Biological Solutions Agree to Exclusive Commercial License of Leading Yield Enhancement Technology

Asilomar Bio and Koch Biological Solutions Agree to Exclusive Commercial License of Leading Yield Enhancement Technology QB3@953 startup, Asilomar has developed a small molecule to improve plant stress response. Koch Biological Solutions, LLC has secured exclusive global rights to commercialize and market products containing Asilomar Bio’s flagship yield enhancement technology for foliar, in-furrow, and other modes of application on a […]

Read more

Logicink announces first product to market: Logicink UV

  On October 19, at Breakout Lab’s Unboxing event, LogicInk, a pioneer in programmable materials, announced its first product to market: LogicInk UV, a wearable that resembles a temporary tattoo and monitors your UV exposure, signaling when it is time to take action to prevent skin damage. The company’s first product, LogicInk UV, targets people concerned about radiation from the sun that can […]

Read more

Siolta Therapeutics wins the Bugs, Drugs, & Beyond QuickFire Challenge

  Johnson & Johnson Innovation, JLABS and the Janssen Human Microbiome Institute (JHMI) launched the second Bugs, Drugs, & Beyond QuickFire Challenge. Taking place in both San Francisco and Cambridge, the Challenge awarded winners with a customized package of support from the JHMI and JLABS, including coaching and $75,000 in funding or entrance to the South San Francisco or Boston JLABS sites, […]

Read more

Indee Labs closed a $1.3M angel round

  Indee Labs closed a $1.3M angel round Indee Labs recently closed a $1.3M angel round and demonstrated functional modification of human primary T-cells with high efficiency (30 to 60%), cell viability (>85%) and recovery (>90%) without T-cell exhaustion or activation. The team also signed its first customer — a clinical-stage biotechnology company developing gene-modified B-cell therapies for rare disease […]

Read more

OneSkin closes $2M Financing to reverse aging skin

  OneSkin closes $2M Financing to reverse aging skin OneSkin Technologies is working on optimizing their technology of in vitro tissue aging and quantitative measurement of anti-aging molecule effects over the age of skin models. This platform will allow them to screen for molecules that molecules that truly rejuvenate skin or prevent aging.

Read more

Naked Biome closes $5M Series Seed Financing for microbiome treatment of acne

Naked Biome closes $5M Series Seed Financing for microbiome treatment of acne Led by dermatologist Dr. Emma Taylor, the Naked Biome team is developing microbiome-based acne therapeutics. They have now closed a $5 million seed round to get them through clinical proof-of-principle.

Read more

Celgene acquires Delinia

Celgene acquires Delinia Three weeks after their graduation party, Delinia announced they had been acquired by Celgene for $300M upfront and up to $475M in milestones. Delinia’s co-founder and CSO, Jeff Greve, began with a single bench at QB3@953 in 2014. Less than two years later, he has delivered an exciting autoimmune candidate to Celgene – now that’s awesome!  

Read more

Top Place in the First Annual Diabetes Innovation Challenge

Top Place in the First Annual Diabetes Innovation Challenge Enable Biosciences was awarded top place in the First Annual Diabetes Innovation Challenge held in Boston for the most innovative late-stage (pre-clinical through translational) technology for their breakthrough ultra-sensitivity antibody assay platform. Press Release

Read more

Nucleo Life Sciences

Nucleo Life Sciences will be expanding their team to broaden the number of formulation and drug development projects they are tackling. Borne out of Actera, another former QB3@953 company, Nucleo Life Sciences incubated with us for a little over one year before outgrowing our location.

Read more

qb3at953 News

Upcoming Event

  • Tosoh Hour

    14:00-15:30
    12/14/2017
    1. HPLC Products 2. Business Development and Venture Investment Our newest sponsor Tosoh will be here on December 14th. Amongst Tosoh's interests is the Separations and Purification Division.  Their scientist, Philip Hoang, will be here and would be happy to meet with you to discuss your purification challenges. He will be joined by Toshifumi Mogami and Kenichi Haga from Tosoh's Venture and Business Development Units. Tosoh is most interested in companies working in diagnostics and research tools.  Please contact Linda Eng if you'd like to meet with them. Toshifumi Mogami, PhD, is Vice President of Business Development & Venture Investment from Tosoh USA, Inc., the venture capital arm of Tosoh Corporation. Toshifumi has a background in biophysics and bioengineering. Kenichi Haga is Senior Vice President of Business Development and Venture Investment from Tosoh USA, Inc. and his background is in organic chemistry. Philip Hoang is an Account Manager of HPLC Columns for the West Coast. He is responsible for sales and support of HPLC/UHPLC columns in California, Oregon and Washington state. Philip received his bachelor’s degree in biology from California State University, Long Beach. He has five years of technical experience in the HPLC and UHPLC field, where his work focused on the analysis of mAbs and ADCs.

Address

953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287
Map

Sign-Up for our Newsletter